- Q3 adjusted EPS $6.99 vs consensus $4.71
Elevance Health beat Q3 estimates with adjusted EPS of $6.99, though $1.85 was nonoperating. Revenue topped forecasts. The company raised full-year guidance and sees at least 12% earnings growth in 2027. Medical cost ratio improved. Stock closed down 1.37%.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.